PRNewswire - December 1, 2008

"We are greatly encouraged by the new, critically important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA President and CEO Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients."

The report found that of the 109 products in development, 29 are vaccines and 57 are antivirals. These drugs are either in human clinical trials or await approval by the U.S. Food and Drug Administration.

Thirty-one medicines to treat HIV/AIDS have been approved since the virus that causes AIDS was first identified more than 20 years ago. The first such medicine was developed in 1987, just four years after the virus was identified. The increased availability and utilization of newer prescription medicines has helped to reduce the U.S. death rate from AIDS substantially in recent years, according to government statistics.

Despite that progress, AIDS remains a devastating and growing worldwide health problem in developing countries, particularly in sub-Saharan Africa, China, India and the Russian Federation. According to the Joint United Nations Programme on HIV/AIDS, in 2007, an estimated 33 million people were living with HIV, 2.7 million new people were infected with HIV, and 2 million died from the disease.

The U.S. Centers for Disease Control and Prevention estimates that more than 1 million Americans were living with HIV infection at the end of 2006.

From 2000 to 2007, America's pharmaceutical research companies contributed more than $9.2 billion to improve health care in the developing world, according to the International Federation of Pharmaceutical Manufacturers & Associations.

The projects they supported included building clinics to treat patients with HIV/AIDS, education and prevention programs, initiatives to prevent mother-to-child transmission of HIV, and donations of medicines for AIDS and related diseases. A number of companies also provide AIDS drugs at reduced prices in many countries.

"With HIV/AIDS medicines, a disease that was once a virtual death sentence can now be controlled and treated as if it were a chronic disease," adds Tauzin. "And the new medicines our scientists are working on right now bring hope for even more promising results in the future."

"While researchers are making exciting progress in the search for new treatments for HIV/AIDS, these efforts are wasted if the medicines that are developed don't get to the patients who need them," said Senior Vice President Ken Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 5 million patients nationwide. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,000 cities.

To read the report Medicines in Development for HIV/AIDS 2008 on the PhRMA Website, go to: http://www.phrma.org/

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://phrma.org/

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://innovation.org/

For information on the Partnership for Prescription Assistance, visit: http://pparx.org/

For information on the danger of imported drugs, visit: http://buysafedrugs.info/

Source: Pharmaceutical Research and Manufacturers of America

CONTACT: Pamela Squires of PhRMA, +1-202-835-3460

Web Site: http://www.phrma.org/

081201
PR081209

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .